跳至主要内容
临床试验/NCT06714019
NCT06714019Enrolling By Invitation不适用

WI241665 2018 GLOBAL ASPIRE TTR Amyloidosis _ Transthyretin Amyloidosis National Registry - a Prospective Non-interventional, Longitudinal, Observational Multicentre Study

National Institute of Cardiology, Warsaw, Poland1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2019年2月11日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
100
试验地点
1
主要终点
disease progression

研究概览

简要总结

We carry out a prospective non-interventional, longitudinal, observational multicentre registry designed to improve our understanding of the epidemiology of TTR amyloidosis in our country. The main objective of the proposed study is to determine the occurrence of TTR amyloidosis and describe clinical profile of patients in the population of our country.

详细描述

Demographic information, TTR genotype, medical history, family history of the disease, and transplant history are assessed at baseline. On return visits, signs and symptoms of the disease are evaluated, general examinations are conducted, and laboratory data, measures of neurologic and cardiovascular function, and quality of life are assessed according to the standard of care for patients.

Specific Aims and Hypotheses

Our working hypotheses are:

  1. TTR amyloidosis affects patients in the population of our country;
  2. there are specific TTR mutations in the population of our country;
  3. there is genotype-phenotype relationship in hereditary TTR amyloidosis;
  4. there are risk factors for TTR amyloidosis in the population of our country. These hypotheses will be tested in our specific aims. In aim 1. we will describe the occurrence of TTR amyloidosis in the population of our country, including the hereditary and acquired forms of the disease.

In aim 2. we will determine and characterize high frequency TTR mutations in the population of our country.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults over 18 years old with confirmed diagnosis of TTR amyloidosis

排除标准

  • Refusal to participate in the study. Light-chain amyloidosis.

结局指标

主要结局

disease progression

时间窗: From enrollment for at least 12 month

Signs and symptoms of the disease are evaluated, general examinations are conducted, and laboratory data, measures of neurologic and cardiovascular function, and quality of life are assessed according to the standard of care for patients.

次要结局

未报告次要终点

研究者

发起方
National Institute of Cardiology, Warsaw, Poland
申办方类型
Other
责任方
Principal Investigator
主要研究者

Monika Gawor-Prokopczyk

PhD

National Institute of Cardiology, Warsaw, Poland

研究点 (1)

Loading locations...

相似试验

PL_GNT01_ISR_Grant 53234273 | 临床试验